Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey, USA.
Prostate. 2022 Aug;82 Suppl 1(Suppl 1):S73-S85. doi: 10.1002/pros.24373.
Our ability to prognosticate the clinical course of patients with cancer has historically been limited to clinical, histopathological, and radiographic features. It has long been clear however, that these data alone do not adequately capture the heterogeneity and breadth of disease trajectories experienced by patients. The advent of efficient genomic sequencing has led to a revolution in cancer care as we try to understand and personalize treatment specific to patient clinico-genomic phenotypes. Within prostate cancer, emerging evidence suggests that tumor genomics (e.g., DNA, RNA, and epigenetics) can be utilized to inform clinical decision making. In addition to providing discriminatory information about prognosis, it is likely tumor genomics also hold a key in predicting response to oncologic therapies which could be used to further tailor treatment recommendations. Herein we review select literature surrounding the use of tumor genomics within the management of prostate cancer, specifically leaning toward analytically validated and clinically tested genomic biomarkers utilized in radiotherapy and/or adjunctive therapies given with radiotherapy.
我们预测癌症患者临床病程的能力在历史上一直局限于临床、组织病理学和影像学特征。然而，长期以来，人们清楚地认识到，这些数据并不能充分捕捉到患者所经历的疾病轨迹的异质性和广度。高效基因组测序的出现引领了癌症治疗的革命，因为我们试图根据患者的临床基因组表型来理解和个性化治疗。在前列腺癌中，新出现的证据表明，肿瘤基因组学（例如 DNA、RNA 和表观遗传学）可用于为临床决策提供信息。除了提供有关预后的判别信息外，肿瘤基因组学可能还掌握着预测对肿瘤治疗反应的关键，这可以进一步用于调整治疗建议。本文综述了肿瘤基因组学在前列腺癌管理中的应用相关的文献，特别侧重于在放疗中使用的经过分析验证和临床测试的基因组生物标志物，以及与放疗联合使用的辅助治疗。
